Shanghai Xunhe Pharma’s CDK4/6 Inhibitor XH-30002 IND Accepted by Chinese NMPA

2020.4.22, according to CDE website, NMPA accepted the IND of CDK4/6 Inhibitor XH-30002 from Shanghai Xunhe Pharma(上海勋和医药), held a pre-IND meeting with NMPA on Dec 2019.

According to the official websites, Shanghai Xunhe Pharma focused on innovation in oncology, cardiovascular, respiratory and mental disease, targeting PARP, JAK2, BET, CDK.

Shanghai Xunhe Pharma completed its first round tens of millions financing in 2018.

Popular posts from this blog

Guideline on the Submission of Clinical Trial Data in China (2020.5 Draft for Public Review)

Drug Review Package of Chinese New Chemical or Biologic Drug